BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $65,080,246 | -29.7% | 956,078 | -15.7% | 0.37% | -20.9% |
| Q2 2023 | $92,575,133 | +9.7% | 1,134,082 | -0.3% | 0.47% | +4.9% |
| Q1 2023 | $84,358,425 | -23.9% | 1,137,059 | -15.0% | 0.45% | -25.0% |
| Q4 2022 | $110,826,410 | -12.2% | 1,337,191 | +200.8% | 0.60% | -6.1% |
| Q3 2022 | $126,241,000 | -27.4% | 444,510 | -11.4% | 0.64% | -21.2% |
| Q2 2022 | $173,936,000 | -51.5% | 501,778 | -39.4% | 0.81% | -29.1% |
| Q1 2022 | $358,309,000 | -28.0% | 827,427 | -13.9% | 1.14% | -8.1% |
| Q4 2021 | $497,439,000 | +8.1% | 961,533 | +1.3% | 1.25% | +13.6% |
| Q3 2021 | $460,148,000 | +6.8% | 949,601 | -0.7% | 1.10% | +8.0% |
| Q2 2021 | $430,659,000 | +35.7% | 956,467 | +15.1% | 1.02% | +22.3% |
| Q1 2021 | $317,430,000 | +17.5% | 831,121 | -2.3% | 0.83% | +18.2% |
| Q4 2020 | $270,170,000 | +37.9% | 850,795 | +7.6% | 0.70% | +23.6% |
| Q3 2020 | $195,915,000 | -0.5% | 790,841 | +6.0% | 0.57% | -12.3% |
| Q2 2020 | $196,979,000 | -28.0% | 745,935 | -48.3% | 0.65% | +7.8% |
| Q1 2020 | $273,736,000 | +55.0% | 1,443,606 | +79.5% | 0.60% | -7.4% |
| Q4 2019 | $176,563,000 | +10.7% | 804,350 | -1.3% | 0.65% | +3.8% |
| Q3 2019 | $159,496,000 | +6.5% | 815,127 | +13.5% | 0.63% | +8.9% |
| Q2 2019 | $149,788,000 | -1.0% | 718,442 | -5.7% | 0.58% | -4.6% |
| Q1 2019 | $151,335,000 | +28.6% | 762,200 | -6.3% | 0.60% | +11.3% |
| Q4 2018 | $117,720,000 | -16.4% | 813,436 | +17.9% | 0.54% | +2.5% |
| Q3 2018 | $140,873,000 | +90.8% | 690,181 | +38.3% | 0.53% | +70.6% |
| Q2 2018 | $73,821,000 | +31.0% | 498,960 | +33.7% | 0.31% | +18.3% |
| Q1 2018 | $56,359,000 | +28.8% | 373,141 | +10.4% | 0.26% | +32.3% |
| Q4 2017 | $43,772,000 | +12.1% | 337,878 | +4.6% | 0.20% | +8.2% |
| Q3 2017 | $39,052,000 | -15.4% | 323,035 | -17.7% | 0.18% | -16.8% |
| Q2 2017 | $46,143,000 | +20.0% | 392,705 | +3.8% | 0.22% | +15.2% |
| Q1 2017 | $38,446,000 | -18.6% | 378,218 | -17.6% | 0.19% | -25.7% |
| Q4 2016 | $47,223,000 | +3.5% | 459,229 | +10.2% | 0.26% | +9.8% |
| Q3 2016 | $45,634,000 | +80.2% | 416,746 | +85.6% | 0.23% | +74.6% |
| Q2 2016 | $25,321,000 | +54.1% | 224,541 | +29.2% | 0.13% | +61.4% |
| Q1 2016 | $16,427,000 | +4.1% | 173,791 | -0.9% | 0.08% | +7.8% |
| Q4 2015 | $15,775,000 | +1.7% | 175,282 | +4.5% | 0.08% | -9.4% |
| Q3 2015 | $15,509,000 | -8.8% | 167,737 | -2.9% | 0.08% | +10.4% |
| Q2 2015 | $17,006,000 | -9.7% | 172,699 | -8.0% | 0.08% | -9.4% |
| Q1 2015 | $18,836,000 | – | 187,816 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |